Hintergrund: Das Hämangiopericytom (HPC) ist ein seltener vaskulärer Tumor, der aus kapillären Pericyten stammt. Ein HPC der Brust ist extrem selten. Fallbericht: Wir beschreiben eine 50-jährige Frau mit einem HPC der Brust und schildern insbesondere die präoperative Diagnose und das Ausmaß der Operation. Unter Lokalanäs-thesie wurde eine vollständige Tumorentfernung vorgenommen. Danach erfolgte eine pathologische Untersuchung auf Basis der Schnellgefrier-Methode, die zur Diagnose «bösartiger Tumor der Brust, vielleicht aus Gewebe der mittleren Brust stammend» führte. Schließlich wurde eine modifizierte radikale Mastektomie durchgeführt, wobei alle 7 Lymphknoten der Entnahmeposition in der Fossa axillaris Symptome einer reaktiven Hyperplasie zeigten. Schlussfolgerung: Auf der Basis der relevanten Literatur schlagen wir eine Reihe von Grundideen vor: Eine sorgfältig durchgeführte Biopsie zusammen mit einer entsprechenden histologischen und immunhistochemischen Untersuchung ist vielversprechend, und da Lymphknotenmetastasen sehr selten sind, kann eine einfache Mastektomie in Erwägung gezogen werden.
Introduction
Hemangiopericytoma (HPC) is a rare vascular tumor originating from the capillary pericytes, which are contractile spindle cells surrounding the capillaries and postcapillary venules [1] . It was first described by Stout and Murray in 1942 as Zimmermann's pericytes which proliferate in the vessel wall [2] . Since then, some cases of HPC in various locations of the body such as the lower extremities, meninges, pelvis, retroperitoneum, trunk, upper extremities, uterus, orbit and oral cavity have been reported [3] . Among these cases, HPC of the breast is extremely rare. Since it is nonspecific in most routine examinations [1] , when diagnosing this disease, a pathological or even immunohistochemical examination may be necessary. In Tang/Wang/Xu this case report, first, we describe a 50-year-old woman who presented with a mass in her breast. We mainly describe the clinical, mammographic and pathological aspects. Second, we propose some of our opinions on this disease regarding diagnosis and therapy.
Case Report
On March 27, 2007, a 50-year-old woman was admitted to our hospital with a persistent augmenting mass in the left breast. The mass was painless and without nipple discharge or hemorrhage. The patient said the mass had enlarged very quickly. It was only about 2 cm × 1 cm when she found the mass about 20 days before she came to our hospital. Her medical history and family history were unremarkable. Physical examination revealed an approximately 5 cm × 5 cm round firm mass at the 10 o'clock position of her left breast, which was painless and without local skin impaction. A lymph node about 1 cm × 1 cm was palpable in the left axillary fossa, which was movable and painless. Mammography revealed a 39.5 mm × 37.6 mm well-circumscribed mass at the 10 o'clock position of the left breast ( fig. 1 ). Since the tumor had enlarged very quickly and there was a palpable lymph node in the axillary fossa, we performed a complete excision of the tumor under local anesthesia. Then, a fast-freezing pathological examination of the tumor was made and led to the diagnostic conclusion of a 'malignant tumor of the breast, perhaps original from lobus intermedius tissue'. Thereafter, we performed a modified radical mastectomy. During the operation, we subjected the palpable lymph node to another fastfreezing pathological examination and reported a 'reactive hyperplasia of the lymph node'. After the operation, we took seven lymph nodes from the axillary fossa position of the excision, which were sent to a systematic pathological examination together with the tumor. The tumor was 5 cm × 4 cm × 4 cm, colored grey and yellow in cross-section, without muscle or skin infiltration. We saw neither necrosis nor calcification of the tumor. The seven lymph nodes were soft without any obvious evidence of metastasis. Histological examination of the mass is shown in figure 2 . All the lymph nodes showed symptoms of reactive hyperplasia. Immunohistochemical examination suggested that the tumor was positive for CD34 and negative for vimentin, desmin, actin, s-100 and CK ( fig. 3 ).
Discussion
HPC of the breast is extremely rare, but its malignant potential is diverse. Therefore, the prognosis of this disease is diverse as well [5] . Currently, there are no guidelines available how to treat a hemangiopericytoma. On the basis of reviewing some pertinent literature, we would like to discuss some problems concerning the diagnosis and the therapy.
Diagnosis
Since it is not specific in most routine breast examinations, including ultrasound, mammography, biochemical or even traditional pathological examination, it is very difficult to thoroughly diagnose this disease before the operation. Moreover, predicting the biologic behavior of HPC based on cytotoxic features is not yet feasible [6] . Core biopsy may be useful in dealing with this disease. There was once a case reported by Buecker et al. [4] : In 2004, a female patient was sent to the hospital and a lump was found in her breast. Then, a core biopsy was performed, but no malignant tissue was found. So they did not treat the tumor. In 2006, since the tumor had enlarged very quickly, another ultrasound-guided core biopsy was performed, with histological and immunohistochemical findings consistent with malignant hemangiopericytoma. Then, the patient underwent a modified radical mastectomy operation [4] . In contrast, as for our patient, we performed a complete excision under local anesthesia for the following reasons: First, the tumor was superficial so that it was easy to excise in its entirety, and the damage was small. Second, the tumor grew very fast, which prognosticated a malignant possibility. Third, there was a palpable lymph node in the axillary fossa before the operation, which also prognosticated a malignant possibility. However, the fast-freezing pathological examination could not definitely diagnose HPC of the breast and it could only be reported as a 'malignant tumor of the breast, perhaps original from lobus intermedius tissue'.
In conclusion, we think that perhaps only an accurate biopsy together with an appropriate histological and immunohistochemical examination may be useful to diagnose this disease.
Therapy
Operation: Kanazawa et al. [7] thought that the extent of surgery depends on tumor size and breast size. In general, lymph node metastases are rare, so complete axillary lymph node dissection does not seem to be necessary [7] . In our case, a modified radical mastectomy was performed on the patient and, as a result, no metastases in the lymph nodes from the axillary fossa position of the excision were found after the operation. This supports the opinion of Kanazawa. However, in order to form guidelines to treat this disease, more cases and systemic clinical trials are needed. Radiotherapy: According to the research of Chugh and Baker [8] , under some circumstances radiotherapy is recommended, for example if the tumor is more than 2 cm in diameter, after incomplete resection, or for tumor reduction before surgery. But there is no authoritative evidence to demonstrate that radiotherapy is necessary for HPC of the breast. As for this patient, we performed a modified radical mastectomy which had a negative surgical margin. Similarly, radiotherapy has side effects, so we did not suggest the patient to have radiotherapy.
Chemotherapy: The role of adjuvant chemotherapy is controversial for patients with soft-tissue sarcomas in general, and even less defined in patients with hemangiopericytoma [9] . Follow-up: For HPC all over the body, recurrence and metastasis are not rare [3] . Although they are not very common for HPC in the breast, we think a lifetime follow-up is necessary. One study suggested that positron emission tomography imaging may be useful for the detection of recurrent HPC during the follow-up [10] .
